Lassman, A. B., Hoang-Xuan, K., Polley, M.-Y. C., Brandes, A. A., Cairncross, J. G., Kros, J. M., Ashby, L. S., Taphoorn, M. J. B., Souhami, L., Dinjens, W. N. M., Laack, N. N., Kouwenhoven, M. C. M., Fink, K. L., French, P. J., Macdonald, D. R., Lacombe, D., Won, M., Gorlia, T., Mehta, M. P., & van den Bent, M. J. (2022). Joint Final Report of EORTC 26951 and RTOG 9402: Phase III Trials With Procarbazine, Lomustine, and Vincristine Chemotherapy for Anaplastic Oligodendroglial Tumors. Journal of Clinical Oncology, 40(23), 2539–2545. https://doi.org/10.1200/jco.21.02543

Tom, M. C., Milano, M. T., Chao, S. T., Soltys, S. G., Knisely, J. P. S., Sahgal, A., Nagpal, S., Lo, S. S., Jabbari, S., Wang, T. J. C., Ahluwalia, M. S., Simonson, M., Palmer, J. D., Gephart, M. H., Halasz, L. M., Garg, A. K., Chiang, V. L. S., & Chang, E. L. (2022). Executive summary of American Radium Society’s appropriate use criteria for the postoperative management of lower grade gliomas. Radiotherapy and Oncology, 170, 79–88. https://doi.org/10.1016/j.radonc.2022.03.018

Mohile, N. A., Messersmith, H., Gatson, N. T. N., Hottinger, A. F., Lassman, A. B., Morton, J., Ney, D., Nghiemphu, P. L., Olar, A., Olson, J., Perry, J., Portnow, J., Schiff, D., Shannon, A., Shih, H. A., Strowd, R., van den Bent, M., Ziu, M., & Blakeley, J. (2021). Therapy for Diffuse Astrocytic and Oligodendroglial Tumors in Adults: ASCO-SNO Guideline. Neuro-Oncology, 24(3), 358–383. https://doi.org/10.1093/neuonc/noab279

Agopyan-Miu, A. H. C. W., Banu, M. A., Miller, M. L., Troy, C., Hargus, G., Canoll, P., Wang, T. J. C., Feldstein, N., Haggiagi, A., & McKhann, G. M. (2021). Synchronous supratentorial and infratentorial oligodendrogliomas with incongruous IDH1 mutations, a case report. Acta Neuropathologica Communications, 9(1). https://doi.org/10.1186/s40478-021-01265-9